1Glade CP, van Erp PE, Boezeman JB, et al. Multiparameter flow eytometry as a tool to evaluate antipsoriatic therapy[J]. Br J Dermatol, 1997, 137(3):367-375.
2Piskin G, Heydendael VM, de Rie MA, et al. Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ[J]. Arch Dermatol Res, 2003, 294(12): 559-562.
3de Rie MA, Hamerlinck F, Hintzen RQ, et al. Quantitation of soluble CD27, a T-cell activation antigen, and soluble interleukin-2 receptor in serum from patients with psoriasis[J]. Arch Dermatol Res, 1991, 283(8): 533-534.
4Borska L, Andrys C, Krejsek J, et al. Serum levels of the pro-inflammatory cytokine interleukin-12 and the antiinflammatory cytokine interleukin-10 in patients with psoriasis treated by the Goeckerman regimen[J]. Int J Dermatol, 2008, 47(8):800-805.
5Garduno J, Bhosle M J, Balkrishnan R, et al. Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review[J]. J Dermatolog Treat, 2007, 18(4):223-242.
6Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid[J]. Dermatologica, 1978, 157(4): 238-244.
7Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?[J]. J Am Acad Dermatol, 2000, 43(2 Pt 1):281-285.
8Feldman SR, Fleischer AB Jr, Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable[J]. J Invest Dermatol, 1996, 106(1): 183-186.
9Finlay AY, Khan GK, Luscombe DK, et al. Validation of Sickness Impact Profile and Psoriasis Disability Index in psoriasis[J]. Br J Dermatol, 1990, 123(6): 751-756.
10Hunt SM, McKenna SP, McEwen J, et al. A quantitative approach to perceived health status: a validation study[J]. J Epidemiol Community Health, 1980, 34(4): 281-286.
